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INTRODUCTION 
Breast cancer remains the most frequent malignant tumor among women in Europe. 
Organized breast cancer screening programs, the mass media, the large number of dedicated 
conferences reveal the high level of epidemiological, sociological and psychological 
significance of this disease. A recent PubMed search identified 369900 different papers on 
breast cancer at the time of writing this thesis. This huge number of publications shows the 
degree if interest in the research on breast neoplasms. In our work, we focused on 
immunophenotyping of triple negative breast cancers (TNBCs), on effects of primary 
systemic therapy (PST) in the tumor bed and in the axillary lymph nodes, and on cases having 
diffuse ductal carcinoma in situ (DCIS) with comedo-like necrosis and amorphous 
calcification, which are potential cases of neoductgenesis. 
1.1. TRIPLE NEGATIVE BREAST CANCER AS A DIAGNOSTIC CHALLENGE 
Metastases of breast cancer develop through either the lymphatic or the blood vessels, 
and affect regional lymph nodes and distant organs. Sometimes, metastasis is the first clinical 
sign of an unknown primary breast cancer. In case of metastatic carcinoma, it is essential to 
prove its metastatic nature and origin. Despite their less than perfect specificity, estrogen 
receptor (ER), progesterone receptor (PR) and human epidermal growth receptor-2 (HER2) 
are among the most useful immunohistochemical (IHC) markers for suggesting breast origin. 
These antibodies can be helpful in cases of luminal A-like, luminal B-like and HER2+ 
subtypes, but not in cases of TNBC which represent approximately 15% of all breast cancers. 
Without the information of a previous primary breast carcinoma, and because of its 
phenotypic overlap with other potential primaries, a triple negative case can easily confuse the 
pathologist. Several immunomarkers as GATA-3, mammaglobin A (MG), gross cystic disease 
fluid protein-15 (GCDFP-15), NY-BR-1 and BRCA-225 have been studied recently to verify 
the breast origin in metastatic cancer. 
1.2. TUMOR REGRESSION AFTER PRIMARY SYSTEMIC THERAPY (PST) IN 
BREAST CANCER 
PST is currently applied in bulky (>2cm) tumors or locally advanced cancers. Despite 
(inter)national guidelines or reviews aiming at some uniformity in breast cancer reporting, 
there are several inconsistencies, namely in specimen work-up, definition of pathological 
complete regression (pCR), patterns and grades of regression. After PST, gross examination 
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must be correlated with the clinical and especially radiological localization to ensure that the 
correct area is sampled. Systematic sampling should include the grossly visible tumor bed or 
the location of clip markers and neighboring areas to incorporate the area involved by 
carcinoma before treatment. 
A less analyzed feature of response to PST is homogeneity or heterogeneity of the 
regression. According to Provenzano and coworkers, the patterns of residual disease are the 
following: homogenous regression (cellularity decreased, size unchanged), inhomogeneous 
regression (cellularity decreased, size variable, small areas without residual disease), "scatter 
pattern" (cellularity decreased, size variable, part of tumor bed slides without residual disease) 
and "concentric shrinkage" (CS) (size decreased, cellularity similar). Especially the "scatter 
pattern" may lead to diagnostic pitfalls if not systematically sampled. After PST, bizarre 
and/or macronucleated neoplastic giant cells generally attributed to the effects of 
chemotherapy may sometimes be found in the tumor bed. The presence of these bizarre cells 
may increase the posttreatment grade, whereas a reduction in the proliferating cells may 
decrease it. 
1.3. TUMOR REGRESSION AFTER PRIMARY SYSTEMIC THERAPY IN AXILLARY 
LYMPH NODES 
The sentinel lymph nodes (SLN) are the first lymph nodes draining the tumor area, 
therefore the SLNs are the first involved during the lymphatic spread of cancer. The non-
SLNs of the same anatomic region develop metastases only subsequently. Tumor-reactive 
lymphadenopathy (TRL) is a complex reaction of lymph nodes, which develops before the 
arrival of the metastatic tumor cells and comprises morphological and functional changes. As 
concerns the morphological alterations, previous publications found enlargement of the tumor 
draining lymph nodes, increased total number of functional blood vessels and lymphatic 
vessels/sinuses, dilation of functional blood vessels with structural remodeling and endothelial 
cell proliferation of high endothelial venules. Functional changes, such as increased blood 
perfusion and immunological differences, like the alterations in CD28 and CD3ζ expression 
of CD4+ and CD8+ T-lymphocytes or the reduction in density and dendritic complexity of 
antigen presenting paracortical dendritic cells were also observed in tumor draining lymph 
nodes.  
The above-mentioned factors may hypothetically alter the neoadjuvant therapy induced 
reactions in tumor-draining SLNs compared to lymph nodes without direct connection with 
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the primary carcinoma, i.e. non-SLNs. Enhanced blood flow and enriched vasculature may 
increase the load of chemotherapeutics or targeted cancer therapy agents (e.g. hormone 
receptor modulators or trastuzumab) in lymph nodes developing TRL. A preferential 
regression in SLNs might influence the false negative rate of SLN biopsy after PST, by 
resulting in complete regression in SLNs with remaining tumor burden in non-SLNs. 
Alternatively an immunosuppressed status of the SLNs as compared to non-SLNs could lead 
to less effect from cytotoxic therapeutics. A selective regression or non-regression may also 
alter the staging effect of the removal of radioactive seed localized nodes that proved to be 
positive before the initiation of primary systemic treatment. 
1.4. BREAST WITH DIFFUSE DCIS WITH COMEDO-LIKE NECROSIS AND 
AMORPHOUS CALCIFICATION –THEORY OF NEODUCTGENESIS 
Breast parenchyma is organized into anatomic units corresponding to mammary lobes. 
An easy to imagine visual analogy of the lobar organization would be that of a tree, where the 
lactiferous duct would correspond to the trunk, the ducts to branches, and the lobules to 
compound leaves. Acini of the lobules and ducts are easy to distinguish from each other. 
Although both the ducts and lobules feature an outer myoepithelial cell layer and a basement 
membrane, there is usually also an elastic layer around the ducts, which is missing around the 
acini. 
When DCIS develops in the ductal tree or its end, the terminal ductulolobular unit, 
there is often a dilatation of the normal anatomic structures. When the anatomy of the breast is 
maintained, DCIS can easily be identified as involving the ducts and sometimes the lobules. 
The latter phenomenon has been called lobular cancerisation. Some forms of DCIS do not 
follow this regular growth and intraluminal spread. Instead, there are plenty of more or less 
dilated lumens dispersed with a relatively uniform and higher than normal density. Although 
some believe that this pattern is also due to abnormal extent of dilatation of pre-existing 
structures, there is apparently no obviously discernible lobular architecture maintained. The 
concept of neoductgenesis has been introduced to explain the morphology of these cancers. 
This concept suggests that new ducts are formed from the pre-existing ones and grow into the 
stroma. Newly formed ducts “invade” the stroma in a pushing and “coated” manner without 
losing their myoepithelial and basement membrane layers which are the diagnostic hallmark 
of in situ carcinomas and the clue used to exclude the presence of invasion in breast 
pathology. Neoductgenesis could explain the aggressive behavior of tumors with this 
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phenomenon having minor areas of classical invasive carcinoma of no special type. Local 
recurrence rates in cases diagnosed as representing pure DCIS are also higher in neoplasms 
with proposed neoductgenesis, and this is also related to their greater extension and diffuse 
growth pattern, but also reflects a worse overall prognosis. 
Neoductgenesis has been associated with casting type calcifications on the 
mammogram, and tumors with this manifestation have been reported to have poor outcome in 
several series. Morphologic criteria have also been proposed by Zhou and coworkers on the 
basis of duct concentration, periductal fibrosis and lymphocytic infiltration and may help to 
identify cases with this phenomenon even on histological slides. 
2. AIMS 
The aims of the present thesis are listed as follows: 
To look at the IHC staining of GATA-3, MG, GCDFP-15, NY-BR-1 and BCA-225 in 
a series of TNBCs showing CK5 expression and therefore being consistent with a basal-like 
phenotype on the basis of the IHC-based surrogate molecular classification. 
To evaluate the response patterns in breast cancers after PST, focusing on correlations 
of radiological and pathological tumor sizes, regression heterogeneity in the tumor bed and in 
the axilla in different molecular subtypes of breast cancer, cellularity changes between biopsy 
and resection specimen, correlation between cellularity and size alterations and the incidence 
of macronucleated, bizarre neoplastic cells related to therapy. 
To evaluate the differences in the degree of regression induced by neoadjuvant therapy 
in the SLNs (tumor draining lymph nodes) and in non-SLNs (non-tumor draining lymph 
nodes) in a series of patients who underwent SLN biopsy and axillary lymph node dissection 
(ALND) following PST for breast cancer. 
To analyze lumen forming structures of the DCIS component of a few tumors (some 
of which were believed to represent DCIS with neoductgenesis) with orcein staining to see 
how ducts and acini maintain their staining when involved by DCIS, and to see how ducts 
believed to be newly formed behave with this stain. 
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3. MATERIALS AND METHODS 
3.1. IMMUNOHISTOLOGICAL EVALUATION OF BASAL-LIKE TNBCS 
Invasive breast carcinomas operated on at the Bács-Kiskun County Teaching Hospital, 
Kecskemét between August 2005 and August 2015 and fulfilling the criteria of TNBC and 
CK5 positivity by IHC were selected for tissue microarray (TMA) construction. The TMAs 
were constructed from archived paraffin-embedded blocks; each carcinoma was represented 
in duplicate in 2 different TMAs. 
IHC for GATA-3, MG, GCDFP-15, NY-BR-1 (and BCA-225) was performed on the 
TMAs and the stains were assessed by the two authors by evaluating the proportion of nuclear 
(GATA-3) and cytoplasmic (MG, GCDFP-15 and BCA-225) or both nuclear and cytoplasmic 
(NY-BR-1) labeling of tumor cells. A staining of 5% or more cells was considered a positive 
result. 
3.2. EVALUATION OF REGRESSION PATTERNS IN BREAST CANCER AFTER PST 
Consecutive invasive breast carcinomas treated with PST and operated on at the Bács-
Kiskun County Teaching Hospital, Kecskemét or at the Department of Surgery, University of 
Szeged from 2015 through February 2018 and from 2013 through May 2018, respectively 
were included. Both departments have used a similar work-up methodology matching the 
recommendations of the 3rd Hungarian Consensus Conference on Breast Cancer, including 
radiological localization, systematic sampling and clinical-pathological correlation. 
All hematoxylin-eosin (HE) stained tumor (bed) containing slides of biopsy and 
excision specimens were analyzed. The cellularity was estimated by two pathologists both on 
biopsy and excision specimens. The presence of whole slides, any low power field (4x; 0.24 
mm
2
) or any medium power field (10x; 0,005 mm
2
) showing complete response or the lack of 
any response was noted. Homogenous regression was defined as pCR, absence of regression 
on all slides and uniform degree of regression on all slides. Any other pattern was perceived 
as inhomogeneous response. The latter included the “scatter pattern", and CS. The alteration 
of pre- and posttreatment cellularity and size; and the correlation between radiological 
(exclusively US data) and pathological size were analyzed by the Spearman rank model. 
The cells having enlarged cytoplasm, multiple and/or enlarged bizarre hyperchromatic 
nuclei with different size and shape (“monster cells” for the purpose of this study) were 
6 
 
looked for in post-PST specimens. The slides of axillary lymph node excisions were 
reevaluated and the presence or absence of metastasis and regression was documented. If 
metastatic nodes were seen with and without regression, inhomogeneous axillary response 
was identified.  
3.3 EVALUATION OF REGRESSION HETEROGENEITY IN AXILLARY LYMPH 
NODES AFTER PST 
In this retrospective study, lymph node tissue sections of 142 female breast cancer 
patients staged with SLN biopsy and ALND after receiving PST were used from the archives 
of the authors’ institutions. The presence and degree of regression were evaluated in all 
metastatic and non-metastatic lymph nodes, SLNs and non-SLNs separately. These results 
were used to categorize the cases, based on whether they supported the theory that regression 
in SLNs may be greater than in non-SLNs or not. 
3.4. ANALYSIS OF LUMEN FORMING UNITS IN CASES OF DIFFUSE DCIS WITH 
COMEDO-LIKE NECROSIS AND CASTING TYPE CALCIFICATION 
Selected histological slides of patients with areas of DCIS (mostly associated with areas 
of invasive cancer) demonstrating comedo necrosis and central calcification from the 
Pathology Departments of the University of Szeged and Bács-Kiskun County Teaching 
Hospital were retrospectively analyzed. HE staining was employed for the identification of 
anatomic structures involved by the in situ neoplastic cells as ducts or acini, whereas orcein 
staining (ORC) was used for the evaluation of elastic fibers around the units previously 
classified on the basis of the HE stain. One or two slides per case were selected and digitized 
with a 3DHistec Pannoramic 250 scanner. The structures were numbered in parallel on both 
the HE and the ORC digital slides with the aid of the Pannoramic Viewer software (3DHistec, 
Budapest, Hungary). 
Each numbered structure was classified according to the resemblance to the normal 
microanatomical structures into one of the following categories: definitely resenting a duct, 
likely to be a duct, unclassifiable, likely to be an acinus, definitely representing an acinus. The 
elastic fibers around the numbered and classified structures were graded as concentric 
presence, dominant presence (elastic fibers around more than half of the perimeter of the 
structure), dominant absence (elastic fibers around less than half of the perimeter of the 
structure) and absence of elastic fibers around the structure; these categories were scored from 
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3 (concentric elastic layer) to 0 (no elastic layer) in descending order. The neoductgenesis-
score described by Zhou et al was applied for the identification of tumors demonstrating 
neoductgenesis. The original description of the score also includes a visual scale for each 
score component, and this was used to label the cases. However, we also applied the score to 
individual structures. For this, we used the first component of the combined score from the 
entire slide, but the two remaining score components were derived from the lymphocytic 
infiltration and fibrosis around the given structure. The statistics included the Mann-Whitney 
and the chi-square tests. We utilized the SPSS Statistics software (IBM, SSPS 22.0, Armonk, 
NY USA). 
4. RESULTS 
4.1. IMMUNIHISTOCHEMICAL EVALUATION OF BASAL-LIKE TNBCS 
All markers could be evaluated in only 115 of the 118 tumors sampled, therefore the 
result are reported for these 115 cases. In 3 cases, the tissue cores were not evaluable due to 
necrosis or lack of tumor cells. GATA-3 labeling was characterized by nuclear staining in the 
tumor cells, whereas MG, GCDFP-15, NY-BR-1 and BCA-225 positivity was identified as 
obvious cytoplasmic staining. Taking any staining into account, GATA3 and BCA-225 
labeling was seen in the majority of the cases, followed by MG and GCDFP-15, whereas NY-
BR-1 immunoreactivity seen in only a few tumor samples. Using the 5% cut-off, there was a 
marked drop in the proportion of cases showing GATA3 positivity, but reductions were seen 
with all markers. 
 
 
Figure 1. Hierarchical 
labeling of the tumors 
 
 
 
Only one third of the cases showed notable (at least 5%) staining with any of the 4 
markers considered to be more specific for a breast origin if a few caveats are kept in mind. 
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Using the frequency of labeling in this series, Figure 1 shows the hierarchical help that each 
of the markers can give in the assessment of a mammary origin of CK5 positive TNBCs. It is 
clear from the figure as from overall data, that NY-BR-1 is not of great help in this context. 
4.2. EVALUATION OF REGRESSION PATTERNS IN BREAST CANCER AFTER PST 
In this series, 106 cases were included: 56 and 50 patients from the University of 
Szeged and the Bács-Kiskun County Teaching Hospital, respectively. Regarding the 
homogeneity of regression, the luminal A-like, HER-2 and TNBCs showed more 
homogeneity, whereas luminal B-like cases demonstrated more inhomogeneity. 
Unfortunately, statistical analysis could not be applied due to the low case numbers in the 
groups. Lack of any regression, uniform degree of regression and pCR were observed in 
7.5%, 18.8% and 28.3% of all cases, respectively. The vast majority of inhomogeneous 
regression was minor inhomogeneity (36.7% of all cases). The scatter pattern was identified 
in only 7 cases (6.6%), while CS was the rarest (n=2; 1.8%). In the lymph node specimens, 
homogeneity was more frequent (homogeneity: 45.3% versus inhomogeneity: 23.5% of all 
cases). In cases having neither metastasis nor regression in the lymph nodes, homogeneity of 
regression or its lack could not be evaluated (31.2 %). 
Cellularity changes reflected decrease in most cases (two thirds of all patients) but an 
increase was recorded in a significant minority (15.1%). The correlations between changes in 
cellularity and the alterations of post-treatment pathological and radiological tumor sizes 
compared to the pretreatment US size were significant (p=0.04 and p=0.03, respectively). The 
grade of tumors was unchanged in 72.4%. Upgrading and downgrading were detected in 10 
and 10 cases (13.8% and 13.8%), respectively. The latter was not seen among patients having 
TNBC. The Spearman rank correlation revealed that the concordance between post-treatment 
pathological size and radiological size (defined by US examination) was high (p=0.002). 
“Monster” cells were seen in 17.9% (n=19) of all cases. They were present in pre- and 
posttreatment grade 2 and 3 tumors exclusively. In 5 cases, upgrading (grade 2 to post-
treatment y-grade 3) was detected in presence of “monster” cells and the monster cells were 
present only (all but one case) in patients who received PST including a taxane. No 
correlation was found between the molecular subtypes and treatment related alteration in 
(pathological) size, cellularity, grade, the homogeneity of regression in lymph node specimens 
and presence of "monster" cells. 
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4.3. EVALUATION OF REGRESSION HETEROGENEITY IN AXILLARY LYMPH 
NODES AFTER PST 
There were 110 ER positive tumors (including 25 HER2 positive cases), and of the 32 
ER negative tumors, 12 were HER2 positive by immunohistochemistry or in situ 
hybridization. A pCR with or without residual in situ carcinoma was seen in 24 cases, and no 
signs of regression were reported in 16 primary cancers. No nodal regression at all was 
evidenced in 19 node-positive cases, whereas the number of cases having at least one 
metastatic lymph node without evidence of regression (NR4) was 55. A median of 2 SLNs 
(range: 1-8) and 14 non-SLNs (range: 2-42) were removed from the patients. 
The practice of SLN biopsy in locally advanced breast cancer patients receiving PST is 
still somewhat controversial. Often the SLN biopsy was performed before primary systemic 
therapy or was not performed because of previously evidenced metastatic lymph nodes. 
Eighty seven from 142 cases including 40 node-positive cases without evidence of regression 
in the lymph nodes, were indifferent towards the tested hypothesis. Of the 89 cases with signs 
of nodal regression, the regression was of greater degree in non-SLNs in 22 cases (25%). 
Only 18/89 cases (20%) were in support of a selective and more pronounced regression in the 
SLNs. 
4.4. ANALYSIS OF LUMEN FORMING UNITS IN CASES OF DIFFUSE DCIS WITH 
COMEDO-LIKE NECROSIS AND CASTING TYPE CALCIFICATION 
Twenty seven slides from 21 female patients were investigated in this retrospective 
study. Altogether 1220 structures were classified as ducts or acini with different levels of 
certitude, as described in the methods. The majority (nearly two thirds) were unclassifiable, 
and between 7.4 and 13.6 per cent belonged to one of the 4 remaining categories each. The 
concentric presence of elastic fibers is more frequent around structures identified as ducts or 
likely ducts, but was also seen around a minority of unclassifiable structures. At the opposite 
end of the spectrum, acini lack elastic fibers around, similarly to likely acini. Most 
unclassifiable structures are also completely or partially (dominant absence pattern) devoid of 
peristructural elastic fibers. The Mann-Whitney test revealed significant difference between 
ducts and acini: a concentric elastic fiber layer surrounds almost all normal ducts, but the 
acini do not have such an elastic coating (p<0.001). 
10 
 
Neoductgenesis was identified in six (25.5%) cases by using the neoductgenesis score. 
After the application of this scoring system to all numbered structures, we found that in 
neoductgenesis positive tumors, 27.3% of the numbered units were suggested as neoducts and 
there was hardly any potential neoducts (0.75%) in neoductgenesis negative tumors. We also 
examined the means of the scores of numbered individual structures per case. In 
neoductgenesis positive tumors (n=6), the average of the neoductgenesis related scores was 
higher (mean±S.D.: 3.87±0.35, range: 3.49-4.39) than in neoductgenesis negative cases 
(mean±S.D.: 1.97±1.11, range: 0-3.1). Two thirds of these neoducts identified by the per 
structure scoring system are irregular and uncertainly classifiable structures, and almost 80% 
of them are not or dominantly not surrounded by elastic fibers. The chi-square test revealed a 
significant difference between the normal structures and the individual score based neoducts: 
the latter generally do not have an elastic layer around (p<0.001). 
In neoductgenesis positive and negative tumors, the presence of elastic fibers was 
evaluated by scoring of each structure on orcein stained slides as described in the methods. 
Lower scores were found in the neoductgenesis positive tumors (mean±S.D.: 0.57±0.32, 
range: 0.28-0.91) than in neoductgenesis negative neoplasms (mean±S.D.: 0.89±0.54, range: 
0.1-2.1). 
5. DISCUSSION 
5.1. IMMUNOHISTOCHEMICAL EVALUATION OF BASAL-LIKE TNBCS 
TNBCs are defined by their negativity for ER, PR and HER2. Metastases to the breast 
are rare, but metastases from TNBCs are relatively common. Proving the mammary origin of 
TNBCs may be problematic, as ER, one of the most commonly used, but not specific marker 
of breast origin is by definition absent in these tumors. In the present study, we investigated 
the expression of 5 markers developed or used to support the mammary origin of cancers 
according to the description in the data sheets. IHC was applied in a series of TNBCs deemed 
to be of the basal-like type on the basis of their CK5 expression. 
Data on the staining frequency of GATA3, MG, GCDFP-15 and NY-BR-1 in TNBC are 
limited. On the basis of these data, the sensitivities of GATA-3, Mammaglobin-A, GCDFP-15 
and NY-BR-1 to suggest a mammary origin are 43.5% (95%CI 0.396-0.476), 16.4% (95%CI: 
0.136-0.196), 15.1% (95%CI: 0.127-0.179) and 5.4% (95%CI: 0.027-0.103), respectively. 
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To our knowledge, this is the largest series of TNBC analyzed for the expression of 5 
markers of mammary origin, moreover the series includes exclusively TNBC of a distinct 
subtype, namely tumors expressing CK5 and therefore most likely to coincide with basal-like 
breast carcinomas. If we consider the documented lack of specificity of BCA-225, the 
remaining 4 breast markers fail to show any staining in about 15% of CK5 expressing 
TNBCs. A more detectable (at least 5%) expression of any of the 4 markers was seen in 
around one third of the cases, leaving the remaining two thirds unidentified as of mammary 
origin. 
The expression of GATA3, MG, GCDFP-15 and NY-BR-1 is lower in TNBCs than in 
breast carcinomas in general. Although these markers may be positive in different other 
tumors, by using them, a subset of basal-like TNBC-s can be identified as of mammary origin. 
Though the positive staining supports a breast origin, negativity for all markers does not 
exclude this. Therefore we suggest using GATA-3, MG and GCDFP-15 as an IHC panel to 
establish breast origin in metastatic tumors when ER and PR are negative. 
5.2. EVALUATION OF REGRESSION PATTERNS IN BREAST CANCER AFTER PST 
In PST studies, the pathological diagnosis is the most important parameter for the 
generation of study endpoints. The histopathological changes after PST are complex, 
therefore careful systematic analysis of the specimen is required for accurate diagnosis and 
treatment. The standardization of specimen handling and histological interpretation is 
essential for approaching pCR as an indicator in PST studies, or for measuring residual 
disease. 
Though the change in cellularity is one of the most representative features of PST, it is 
not recorded routinely in the histopathological reports. In the present series, biopsies taken 
before PST and resection specimens were evaluated for cellularity changes. In the vast 
majority of the cases, cellularity has declined and a significant correlation was detected 
between alterations of cellularity and (pathological) size. 
Our findings suggest that homogeneity and inhomogeneity of regression are not 
associated with any molecular subtype, and both are present approximately in half of the 
cases. The majority of inhomogeneous regression represented minor inhomogeneity seen in 
differences between one and the other medium or low power field, while the scatter pattern 
and CS were exceptionally rare. Although the most remarkable pattern is the scatter pattern 
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regarding the problems of tumor bed sampling, as complete slides may be present without 
residual cancer, minor heterogeneity may also cause diagnostic controversy if only core 
biopsies are taken after PST. Several ongoing or completed studies on PST feature post-PST 
core biopsies as parts of their design. Tumor heterogeneity, especially the scatter pattern of 
regression may have an impact on these studies. Limited sampling of inhomogeneously 
responsive cases by taking interim or final biopsies may be the source of misinterpretations, if 
the biopsy is taken from the part of tumor bed showing complete response or another part 
lacking any response. To avoid these diagnostic pitfalls, generous sampling by multiple 
biopsies is recommended if the assessment of the complete tumor bed is not feasible. 
Monster cells are giant tumor cells often associated with effects of PST. The presence 
of these cells was associated with taxane treatment. The principal effect of taxanes is the 
disruption of microtubule function, including the blockage of the mitotic spindle. Our findings 
suggest that the presence of these monster cells may increase nuclear atypia and therefore it 
may lead to upgrading following PST. Due to polyploidization, such cells are also expected to 
show an increased copy number of many genes, including HER2, leading to a post-treatment 
positive status of questionable therapeutic significance in these cells. 
To our knowledge, this is the first study describing the distribution of regression 
heterogeneity according to molecular subtypes. Our findings suggest that regression may be 
inhomogeneous in half of the cases, and it does not seem to be related to any molecular 
subtype. The evaluation of the whole tumor bed is recommended for the best assessment of 
regression. “Monster” cells are related to PST including taxanes, and may cause upgrading in 
tumors with non-high grade nuclei at the start of PST. 
5.3. REGRESSION HETEROGENEITY OF AXILLARY LYMPH NODES 
Altogether the case numbers are relatively small, however, the distribution of the cases 
did not point in favor or against a selective regression (or non-regression) in SLNs. The 
fibrotic foci in the lymph nodes were interpreted as signs of regression, but these signs are not 
specific, and other processes may lead to the same morphological features. However, in the 
setting of neoadjuvant therapy, this latter is the most likely cause for these morphological 
changes, and therefore these were uniformly interpreted as signs of regression. The evidence 
gathered from the limited number of cases available suggests that despite the attractiveness of 
a preferential regression (or non-regression) in tumor draining lymph nodes (SLNs which 
seem to be immunosuppressed and at the same time are the sites of TRL), there is no obvious 
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difference in the degree of regressive histological changes shown by SLNs and NSLNs. 
Therefore, this phenomenon may not be a major contributor to the somewhat higher false 
negative rate of SLN biopsy after neoadjuvant treatment. 
5.4. DIFFUSE DCIS WITH COMEDO-LIKE NECROSIS AND AMORPHOUS 
CALCIFICATION 
Our study of a large number of breast microanatomic structures suggests that most of 
the densely packed structures involved by morphological DCIS with comedo necrosis cannot 
be classified on the basis of the HE look as ducts or acini. The study also demonstrated that 
DCIS involved structures that could be classified as ducts or acini with some certainty 
displayed the elastic coating expected on the basis of the normal anatomic structures. On the 
other hand, most structures that could not be reliably classified as ducts or acini, in parallel 
with most structures classified as representing neoducts on the basis of the proposed scoring 
system adapted to the individual structures were devoid of an elastic coating. Although this 
could be used as a support to the acinar origin of these structures, it is more realistic to 
suggest that together with previously described stromal periductal tenascin-C accumulation, 
this could be another difference between preexisting and newly formed ducts. 
Myoepithelial cells have been reported to have an altered phenotype in some DCIS 
cases, characterized by the loss of one or more myoepithelial markers labeling the 
myoepithelium around normal anatomic mammary structures. Although we did not study the 
expression of myoepithelial markers, we detected another abnormality of high grade DCIS 
cases with comedo necrosis, namely the lack of elastic fibers around the ducts. 
Neoductgenesis is a concept to explain the morphology of certain breast cancers that 
show neoplastic cells in densely packed anatomic structures seemingly corresponding to 
either normal ducts or acini on the basis of the presence of a basement membrane and a 
myoepithelial layer at the outer surface, but not corresponding to any of these preexisting 
structures when looking at the lack of the tree-like distribution of normal anatomic structures. 
The theory suggests that some breast carcinomas are characterized by the outgrowth of new 
branches, i.e. new ducts, neoducts from the ductal tree, representing a pushing type 
infiltration. Three-dimensional analysis of such cases further reinforces the lack of normal 
distribution of ducts and acini in such tumors. This “disturbed arborization” could be the 
result of a disturbed alveolar switch, a hormonally driven physiologic mechanism responsible 
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for the development of acini from ductal epithelium. Our report indicates that the proposed 
neoducts are also devoid of elastic coating, resembling acini in this respect. 
There were more structures that could not be reliably classified as ducts or acini than 
structures corresponding to neoducts on the basis of the neoduct scoring applied to the 
individual structures. These unclassifiable structures were generally devoid of elastic fibers. 
Our study therefore identifies possible neoducts as structures devoid of elastic periductal 
fibers and most of the structures that could not be classified as (likely) ducts or (likely) acini 
on the basis of distribution patterns as similarly devoid of elastic fibers and possibly also as 
neoducts. The use of elastic stains may probably be an aid in the study of neoductgenesis. 
6. MAJOR NEW FINDINGS 
To our knowledge, this is the largest series of TNBCs, more specifically CK5 
expressing basal like TNBCs assessed with 5 potential IHC markers suggestive of breast 
origin. 
The expression of GATA3, MG, GCDFP-15 and NY-BR-1 is lower in TNBCs than in 
breast carcinomas in general. With a 5% staining cut-off more than half of the CK5-positive 
TNBCs cannot be proven to be of mammary origin. 
This is the first study to assess the degree of heterogeneity in regression after PST and 
look for possible associations with molecular subtypes. Our findings suggest that regression 
may be inhomogeneous in about half of the cases, and it does not seem to be related to any 
molecular subtype. 
It is suggested that optimally the whole tumor bed should be investigated for the best 
assessment of regression, and limited sampling by core biopsy might not be suitable in all 
cases for the evaluation of the presence and degree of regression. 
The neoplastic “monster” cells are related to PST including taxanes, and may cause 
upgrading in tumors with non-high grade nuclei at the start of PST. 
Our study of the distribution of lymph node metastases and regression on a limited 
number of cases do not support a selective regression in SLNs, and therefore this phenomenon 
cannot explain the somewhat higher false negativity rate of post-PST SLN biopsies. 
15 
 
The structures involved by DCIS that cannot be classified as ducts or acini on the basis 
of the HE stain and the normal microanatomic distribution do not show an elastic coating 
characteristic of normal ducts and therefore resemble to acini or are atypical ducts.Structures 
corresponding to neoducts on the basis of the neoduct score also show a lack of elastic coating 
and cannot be classified as duct or acini on the basis of microscopic features and distribution. 
The use of elastic stains may probably be an aid in the study of neoductgenesis. 
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